RT Journal Article SR Electronic T1 Dermokine Expression in Intraductal Papillary-Mucinous Neoplasm and Invasive Pancreatic Carcinoma JF Anticancer Research JO Anticancer Res FD International Institute of Anticancer Research SP 4405 OP 4412 VO 32 IS 10 A1 KENJI WATANABE A1 TOSHIYA OOCHIAI A1 SHOJIRO KIKUCHI A1 TATSUYA KUMANO A1 TAKESHI MATSUI A1 KOJI MORIMOTO A1 SATORU YASUKAWA A1 SHOJI NAKAMORI A1 MITSURU SASAKO A1 AKIO YANAGISAWA A1 EIGO OTSUJI YR 2012 UL http://ar.iiarjournals.org/content/32/10/4405.abstract AB Background: Serum dermokine (DK) is a novel biomarker for early colorectal cancer. To our knowledge this is the first study of DK expression in intraductal papillary mucinous neoplasm (IPMN) and pancreatic cancer. Materials and Methods: DK expression in human pancreatic cancer cell lines and tissues was assessed. We compared the sensitivities of common diagnostic markers, carbohydrate antigen 19-9 (CA19-9), carcinoembryonic antigen (CEA), s-pancreas-1 antigen (SPAN-1), pancreatic cancer-associated antigen (DUPAN-2), and Nation Cancer Center-Stomach-439 (NCC-ST-439) in 26 patients with pancreatic neoplasms. Results: DK was expressed in pancreatic cancer cell lines. Immunohistochemical staining revealed that DK was expressed in atypical and cancerous tissues, but not in the normal pancreatic tissues. Serum DK was relatively high in patients with IPMN. The sensitivities of a serum multimarker test including DK was 76.5% (n=13/17) for IPMA/IPMC/invasive carcinoma derived from IPMN, and 100% (n=9/9) for ordinary invasive ductal carcinoma. Conclusion: Serum DK is a potential biomarker in IPMN and invasive ductal carcinoma, when used in combination with conventional biomarkers.